drugset / Trial / NCT07378527

Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria

NCT07378527 ↗

Phase 2/3 Recruiting 344 enrolled Beijing InnoCare Pharma Tech Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of ICP-332 in moderate to severe chronic spontaneous urticaria subjects inadequately controlled by second generation H1-antihistamines

Timeline

Start
2026-02-13
Primary completion
2028-09
Completion
2028-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ICP-332 Unknown — —